Essential Role of PKCδ in Apoptosis Induction of Mouse Thymocytes

1Lutz-Nicoladoni, C., 1Letschka, T., 2Leitges, M. 3Villunger, A and 1Baier, G.
1Department for Medical Genetics, Molecular and Clinical Pharmacology
Innsbruck Medical University, Austria
2Medical University, Hanover, Germany

Abstract: The family of protein kinases C (PKCs) has been implicated in signal transmission leading to apoptosis induction and/or survival. These effects are cell type and tissue dependent. Numerous studies employing phorbol ester, a pleiotropic PKC activator, strongly implicated PKC in apoptosis induction of thymocytes. However, phorbol esters activate both, the conventional PKCs (PKCα, β, γ) as well as the novel PKCs (δ, ε, η and θ), the PKC isotype(s) selectively involved in this process have not been established. In this study we used selective pharmacological PKC inhibitors and our established set of PKC knockout mice to define the PKC isotype that is involved in cell death induction of thymocytes. Pharmacological inhibition of nPKCs and in particular gene ablation of PKCδ, results in a profound reduction of p53-dependent as well as independent apoptosis induction. In strict contrast, loss of conventional PKCs as well as loss of two other thymocyte-expressed nPKC family members, PKCε and PKCθ, does not significantly affect thymocyte apoptosis. Taken together, we define an essential and non-redundant pro-apoptotic role of PKCδ in regulating distinct signaling mechanisms that are required to provoke apoptosis of mouse double positive thymocytes in vitro.

Key words: Phorbol esters, PKC isotypes, thymocytes, apoptosis induction

INTRODUCTION

Protein kinase Cs (PKCs) are members of the serine/threonine protein kinase family, originally identified by Nishizuka and colleagues in 1977 as cyclic nucleotide-independent kinases[1]. Members of the PKC family have been implicated in numerous cellular responses including cell growth and differentiation, cell cycle control, homeostasis, synaptic transmission, ion fluxes, secretion and tumorigenesis of a wide range of cell types and tissues[2]. According to their molecular structure and cofactor dependency they are classified into conventional PKCs (cPKCs) PKCα, β, γ and novel PKCs (nPKCs) PKCδ, ε, η and θ as well as atypical PKCs (aPKCs) PKCζ and PKCλ. cPKCs require Ca²⁺ and diacylglycerol for activation, nPKCs are Ca²⁺ independent and aPKCs neither require Ca²⁺ nor diacylglycerol. Some of the isotypes exist as different splice variants[3]. All PKC isotypes listed, except PKCγ are expressed in T cells. Among them PKCα, PKCδ, PKCε and PKCθ are highly expressed[4]. PKCs are known to phosphorylate several cellular proteins, leading to modulation of surface antigens, activation of other protein kinases and induction of several key transcription factors, including aberrant signalling responses contributing towards malignant transformation[5].

Apoptosis or programmed cell death is a physiological process during thymic development. Thymic selection of immature T cells occurs at CD4⁺CD8⁺ double positive (DP) stage[6,7]. Only clones that will recognize foreign antigens associated with self-MHC molecules are positively selected to survive and differentiate into CD4⁺ or CD8⁺ single positive (SP) T cells (positive selection)[8,9]. On the other hand a high avidity T cell receptor (TCR) interaction promotes apoptosis of developing thymocytes (negative selection)[8-10]. Both, positive as well as negative selection, depend on direct cell-cell interactions between DP thymocytes and thymic stroma cells. However it is still unclear which intracellular signaling pathways are responsible for thymic selection. Deregulation of apoptosis is a hallmark of many diseases such as lymphoid cancers as well as autoimmunity[11].

The process of apoptosis is regulated at several levels through phosphorylation by many different protein kinases. The PKC family has been shown to exert both inhibitory and stimulatory influences, depending on cell type and stimulus for apoptosis induction. Generally, PKCα, β, ε as well as atypical PKC isotypes are considered to be involved in anti-apoptotic pathways, whereas PKCδ and PKCθ are considered to be involved in promotion of cell death[12]. Previous studies with mouse thymocytes and phorbol esters, pleiotropic PKC activators, however, revealed controversial results: DNA fragmentation induced by calcium ionophore or glucocorticoids in thymocytes

Corresponding Author: Dr. Gottfried Baier, Innsbruck Medical University, Schoepfstraße 41, A-6020 Innsbruck, Austria/Europe, Tel: +43 (512)/507-3451, Fax: +43 (512)/507-2861
was abrogated by phorbol ester treatment, indicating an anti-apoptotic role of PKCs\textsuperscript{[13]}. On the other hand, phorbol ester treatment in thymocytes was shown to enhance apoptosis induced by tyrosine-kinase inhibitors, implying that PKC promotes apoptosis\textsuperscript{[14]}. More recent studies, mostly using PKC specific pharmacological inhibitors, revealed both, an anti-apoptotic and a pro-apoptotic role of PKC isotypes in thymocytes. Simon and co-workers suggested PKC\varepsilon as a negative regulator of negative selection of DP thymocytes\textsuperscript{[15]}. Consistently, phorbol ester was also found to prevent immature thymocytes from spontaneous as well as glucocorticoid-induced apoptosis\textsuperscript{[16,17]}. On the other hand the activation of nPKCs, especially the PKC\theta isotype, was suggested to promote a pathway for negative selection\textsuperscript{[18,19]}. Along this line, a positive involvement of PKCs in glucocorticoid-induced apoptosis\textsuperscript{[20]} as well as a role of PKCs in peptide-specific cell death\textsuperscript{[21]} was postulated.

This in part contradictory nature of these results occurred primarily from the use of phorbol esters as PKC activators, because they stimulate both, cPKCs and nPKCs. Additionally, phorbol esters also target receptors other than PKC, a concept that has been largely ignored in the past. In this study we used selective PKC inhibitors and for the first time, our established set of PKC knock out mice to now genetically define the distinct PKC isotypes that are involved in apoptosis induction of thymocytes. To investigate the potential role of PKCs in different apoptosis pathways, we induced apoptosis employing various agents, namely phorbol-12,13-dibutyrate (PDBu) (role in apoptosis\textsuperscript{[22-26]}), the calcium ionophore ionomycin\textsuperscript{[27]}, staurosporine, an inhibitor of phospholipid/Ca\textsuperscript{2+} dependent kinases mediating mitochondrial dysfunction\textsuperscript{[28]} dexamethasone, a glucocorticoid regulating T cell survival, growth and differentiation\textsuperscript{[29,30]}, concanavalin A, a mitogenic plant lectin that mimics the effects of high avidity TCR ligation\textsuperscript{[32]} and two agents inducing DNA damage, camptothecin\textsuperscript{[33]} and etoposide\textsuperscript{[34]}. FasL, a protein belonging to the tumor necrosis factor (TNF) family of cytokines was used to induce the extrinsic death receptor apoptotic pathway\textsuperscript{[35]}. Finally, apoptosis was also induced by TCR crosslinking via anti CD3.

**MATERIALS AND METHODS**

**Mice:** C57/Bl6 wild-type mice were obtained from the animal facility of the Medical University of Vienna, Himberg, Austria. For knock out studies mice lacking a specific PKC isotype, which have been described elsewhere (PKC\alpha\textsuperscript{[36]}, PKC\delta\textsuperscript{[37]}, PKC\theta\textsuperscript{[38]} and PKC\varepsilon\textsuperscript{[39]}) were used. p53 knock out mice were provided from A. Villunger.

**Genotyping of mice:** DNA was extracted from adult tail tissue. Genotyping of the PKC\delta, PKC\varepsilon and PKC\theta alleles was performed by southern blot analysis or PCR was described (PKC\delta), (PKC\varepsilon), (PKC\theta)\textsuperscript{[37,38,40]}. The PKC\alpha allele was genotyped by PCR using the primers PKC\alpha 3’ prime E2 (5’-CCT GGT GCC AAT GGG TGA TCT ACA C-3’) and PKC\alpha 5’ prime E2 (5’-GAG CCC TTG GGT TTC AAG TAT AGA-3’) [Pfeifhofer, unpublished data].

**Preparation of thymocytes:** Thymi were taken from 6-8 week old mice. Cells were singularized by mashing the organ in a strainer and raising the cell suspension through a syringe three times. Cells were washed in RPMI medium (Sigma Aldrich) and used for the assay.

**Apoptosis detection:** Freshly isolated thymocytes were plated in 96-well plates at a density of 2.5x10\textsuperscript{5} cells per well in a total volume of 200\textmu l in RPMI medium (Biochrom) supplemented with 10% heat-inactivated fetal calf serum, 2mM L-glutamine and 50 u mL\textsuperscript{-1} penicillin/streptomycin (all from Biochrom). For some experiments cells were preincubated with distinct PKC inhibitors for 90 min prior to apoptosis induction. G66850 and G6976 were obtained from Calbiochem. The pan PKC LMW Inhibitor was obtained from Altana Pharma. Inhibitors were used at a concentration of 500nM. Apoptosis induction was performed by TCR crosslinking (10 \mu g mL\textsuperscript{-1} anti CD3 2C11, precoated) +/- anti CD28 (1 \mu g mL\textsuperscript{-1}) or by addition of either concanavalin A (10 \mu g mL\textsuperscript{-1}), phorbol-12,13-dibutyrate (1 \mu g mL\textsuperscript{-1}), ionomycin (1 \mu g mL\textsuperscript{-1}), camptothecin (1\muM), etoposide (10 \mu g mL\textsuperscript{-1}), dexamethasone (1nM), staurosporine (100nM) or FasL (100 ng mL\textsuperscript{-1}) plus enhancer for FasL (1 \mu g mL\textsuperscript{-1}) for up to 72 h. FasL and enhancer for FasL were purchased from Alexis, anti CD28 from BD Pharmingen and all other agents were obtained from Sigma-Aldrich. Cells were harvested at time points between 10 and 72 h after apoptosis induction. Late apoptotic and necrotic cells were stained with propidium iodide (5 \mu g mL\textsuperscript{-1}) in PBS. Percentage of viable cells was determined by FACS analysis employing the FACScan\textsuperscript{TM} Cytometer (Becton Dickinson) and CellQuest\textsuperscript{TM} software.

**RESULTS**

**PKC inhibition selectively prevents phorbol ester induced apoptosis:** In order to investigate the role of distinct PKC isotypes in apoptosis induction of mouse double positive thymocytes we induced apoptosis \textit{ex vivo} in thymocytes derived from wild-type C57/Bl6 mice, which were preincubated with pan PKC LMWI, inhibiting both, the conventional PKCs, PKC\alpha and PKC\beta, as well as the novel PKCs, PKC\delta, PKC\varepsilon, PKC\theta and PKC\eta or DMSO as buffer control. Apoptosis was induced by various apoptosis inducing agents, as indicated. As result, we observed a strong protection of PDBu induced apoptosis in cells preincubated with the
pan PKC LMWI (Fig. 1A). In contrast, PKC inhibition did not affect apoptosis induced by TCR crosslinking (Fig. 1B), concanavalin A (Fig. 1C), dexamethasone (Fig. 1D), ionomycin (Fig. 1E), staurosporine (Fig. 1F), camptothecin (Fig. 1G) or etoposide (Fig. 1H).

Essential role of novel PKC isotypes in phorbol ester induced apoptosis: To further investigate which isotype might be involved in phorbol ester induced apoptosis we treated wild-type thymocytes with different PKC inhibitors either inhibiting conventional and novel PKCs (Gö6850 and pan PKC LMWI) or inhibiting selectively the conventional PKCs (Gö6976). As result, both pan PKC LMWI prevented thymocytes from PDBu induced apoptosis while cPKC inhibition did not (Fig. 2). These data suggested a proapoptotic role of at least one of the novel PKCs, PKCα, PKCε, PKCθ or PKCδ. Furthermore and employing thymocytes derived from a p53-deficient mouse line, this proapoptotic action of nPKCs appears independent of p53 function (Fig. 3).

Proapoptotic role of PKCδ in apoptosis of mouse thymocytes: Consistent with the results obtained in studies with pharmacological PKC inhibitors, experiments with our established set of PKC knock out mice revealed a proapoptotic role of PKCδ in phorbol ester induced apoptosis of mouse thymocytes (Fig. 4A). Heterozygous PKCδ+/− thymocytes demonstrated an intermediate phenotype. Importantly, thymocytes derived from our PKCε or PKCθ deficient mice were indistinguishable from wild-type littermates (Fig. 4B and 4C). PKCε or PKCθ deficiency also did not affect apoptosis induced by ionomycin, concanavalin A, dexamethasone, staurosporine, camptothecin, etoposide or TCR crosslinking (data not shown). As a representative member of the cPKC family, PKCα−/− deficient thymocytes were tested as well. Consistently, with the data collected with experiments employing PKC inhibitors, we did not observe any effects in PKCα−/− thymocytes in respect to apoptosis induction by PDBu (data not shown), as well as ionomycin,
Fig. 4: Proapoptotic role of PKCδ in phorbol ester induced apoptosis versus normal ex vivo survival of PKCδ deficient and PKCθ deficient thymocytes. Thymocytes from PKCδ\(^{-/-}\), PKCθ\(^{-/-}\) and PKCδ\(^{-/-}\) knock out mice and wild-type littermates were plated into 96-well plates at a density of \(2.5 \times 10^5\) cells per well. Apoptosis was induced by addition of phorbol-12,13-dibutyrate. Percentage of viable cells was determined by FACS analysis. Results shown for PKCδ\(^{-/-}\) (A) are the means +/- SD of two independent experiments. For PKCθ\(^{-/-}\) (B) and PKCδ\(^{-/-}\) (C) one representative experiment out of two is shown.

Interestingly, deficiency of PKCδ additionally protects thymocytes from apoptosis by TCR crosslinking (Fig. 5A and 5B), dexamethasone (Fig. 5C), FasL (Fig. 5D), staurosporine (Fig. 5E) and etoposide (Fig. 5F). No significant effect of PKCδ could be observed in cells treated with concanavalin A (Fig. 5G) and ionomycin (Fig. 5H).

**DISCUSSION**

Previous studies of the role of the PKC family in apoptosis induction of thymocytes led to very oppositional results due to the application of phorbol esters as PKC activators. Proapoptotic effects\(^{[14,18-21]}\) as well as antiapoptotic effects\(^{[13,16,17]}\) were suggested. Phorbol esters are known to activate both the conventional PKCs (PKC\(\alpha, \beta, \gamma\)) as well as the novel PKC family members (PKCδ, ε, η, θ), making it impossible to define the exact functional roles of distinct PKC isotypes in cell survival and/or apoptosis.

In order to identify the exact PKC isotypes positively or negatively involved in apoptosis of primary mouse double positive thymocytes we used selective PKC inhibitors and observed a proapoptotic role of novel PKCs in PDBu induced apoptosis (Fig. 1A and Fig. 2). Beside developmental apoptosis, programmed cell death is necessary as a cellular stress response, for example to agents inducing DNA damage as well as for activation induced cell death. Here and in contrast, pharmacological PKC inhibition neither affected DNA damage induced apoptosis by etoposide or camptothecin nor glucocorticoid induced apoptosis by dexamethasone nor ionomycin, by staurosporine, by concanavalin A or anti CD3 mediated TCR crosslinking (Fig. 1B-H).

Using thymocytes from all available novel PKC knock out mice we demonstrated the involvement of PKCδ (Fig. 4A and Fig. 5, but neither PKCε (Fig. 4B) nor PKCθ (Fig. 4C) in apoptosis induced by PDBu, dexamethasone, FasL, staurosporine or etoposide. In contrast to the results obtained employing the pan PKC LMWI, knock out studies revealed that PKCδ is
involved in various apoptotic pathways and that the promotion of apoptosis is not restricted to phorbol ester induced apoptosis. Ionomycin and concanavalin A were in fact the only substances where we did not observe reduced apoptosis of PKCδ-/- and PKCδ+/- cells (Fig. 5). This difference between inhibitor and knock out studies most likely is due to the fact that there always remains a residual activity of PKC isotypes upon pharmacological inhibition whereas in the knock out studies, it does not.

Investigations of different cell types postulated an essential role of PKCδ in apoptosis induction. For example, PKCδ was found to be activated during spontaneous apoptosis of neutrophils, in ventricular myocytes under hypoglycemic conditions, in various cell types in respond to H2O2, manganese containing compounds and ceramide. The extrinsic apoptotic pathways mediated by TNF-α and FasL were shown to result in activation of PKCδ, too. Also DNA damage by UV-radiation, ionizing radiation or etoposide is associated with PKCδ activation. Along this line, inhibition of PKCδ was shown to protect various cell types from various apoptotic inducers, indicating that PKCδ acts as proapoptotic signaling molecule. As potential downstream effectors, proapoptotic BH3-only proteins are likely. Consistently, thymocytes from puma-deficient mice were shown to be resistant to phorbol ester induced apoptosis and also demonstrated reduced apoptotic responses to stress stimuli as well as to staurosporine or glucocorticoid treatment. DNA damage and oncogenes activate the proapoptotic BH3-only protein puma via the Mdm2-p53 pathway, while PMA, ionomycin, staurosporine and dexamethasone lead to p53 independent activation of puma. Along this line we demonstrated that the protection of PDBu induced apoptosis in cells preincubated with a pan PKC inhibitor is independent of p53 (Fig. 3).

Taken together, we thus establish a physiological and non-redundant proapoptotic role of PKCδ but not PKCa, ε, nor θ in apoptosis induction of mouse DP thymocytes.

ACKNOWLEDGMENT

This work was supported by grants of the FWF (P16229-B07 + SFB021) and by a cooperation agreement with Altana Pharma (Konstanz, Germany). We are grateful to Miriam Erlacher (from the Division for Pathophysiology, Innsbruck, Austria) for providing the p53+/- knock out mice. Thanks also to Drs. Christa Pfeilhofer, Thomas Gruber and Nikolaus Thuelle (all from the Department for Medical Genetics, Molecular and Clinical Pharmacology, Innsbruck, Austria) for the breeding of PKCa+/-, PKCe+/- and PKCδ+/- mice. All experiments comply with the current laws of Austria.

Abbreviations: DMSO, dimethyl sulfoxide; DP, double positive; FACS, fluorescence activated cell sorter; FasL, Fas ligand; aPKCs, atypical PKCs; cPKCs, conventional PKCs; nPKCs, novel PKCs; pan PKC LMWI, pan PKC low molecular weight inhibitor; PDBu, phorbol-12,13-dibutyrate; PKC, protein kinase C, SD, standard deviation; SP, single positive; TCR, T cell receptor; TNF, tumor necrosis factor; VP16, Etoposide, wt, wild-type.

REFERENCES

Am. J. Immunol., 1 (1):14-20, 205


